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Parkinson’s  disease  (PD)  and  associated 
dopaminergic medications, such as levodopa 
and  dopamine  agonists,  have  differential 
effects on cognition. Dopamine medications 
might either enhance or impair cognition in 
PD patients depending on type of cognitive 
task and medication used. In a recent neu-
ropsychological study, Graef and colleagues 
have tested the effects of PD and levodopa 
monotherapy on feedback and reversal learn-
ing. In feedback learning, subjects learn to 
select  stimuli,  based  on  either  rewarding 
(positive) or punishing (negative) feedback 
to  their  responses.  Thus,  reward  learning 
involves  learning  to  select  responses  that 
lead to reward, while punishment learning 
involves  learning  to  avoid  responses  that 
lead to negative outcome. In reversal learn-
ing tasks, subjects initially learn to associate 
different stimuli with different responses, and 
subsequently learn to associate the same stim-
uli with the opposite responses (i.e., reversal). 
Graef et al. have found that levodopa enhances 
reward learning but impairs reversal learn-
ing in PD patients. This finding is consistent 
with earlier reports that dopamine medica-
tions enhances reward learning (Frank et al., 
2004; Moustafa et al., 2008a; Bodi et al., 2009; 
Palminteri et al., 2009) but impairs reversal 
learning (Swainson et al., 2000; Cools et al., 
2001) in PD patients.
One notable aspect of the current study 
is Graef et al. have tested PD patients on 
levodopa only. This is contrasted from prior 
studies that have recruited PD patients on 
multiple  therapies  including  levodopa  and 
dopamine agonists (Cools et al., 2001; Frank 
et al., 2004; Moustafa et al., 2008b; Bodi et al., 
2009), thus confounding dissociable effects of 
levodopa vs. dopamine agonists on cognition. 
Furthermore, the Graef et al. findings are in 
agreement with other studies showing that the 
administration of levodopa enhances feedback 
learning in rats (Pavlis et al., 2006), healthy 
subjects (Knecht et al., 2004; Pessiglione et al., 
2006; Floel et al., 2008; Pleger et al., 2009), 
stroke  patients  (Scheidtmann  et  al.,  2001; 
Rosser et al., 2008), and PD patients (Beeler 
et al., 2010; de Vries et al., 2010).
Interestingly, Graef et al. have also found 
that  the  administration  of  different  doses 
of levodopa to PD patients does not affect 
reward learning, that is, levodopa has no dose 
effect on reward learning. This is in line with 
the fact that levodopa is a dopamine pre-
cursor, taken up by dopamine neurons and 
converted into dopamine, and thus largely 
produced in natural conditions. Accordingly, 
an increase of doses of levodopa may not sig-
nificantly alter presynaptic dopamine levels 
in the basal ganglia, and thus may not impact 
cognition, as reported in the Graef study. This 
is, however, contrasted with the effects of dif-
ferent doses of dopamine agonists on cogni-
tion. For example, studies have found that 
in healthy subjects, a low-dose (1.25 mg) of 
the dopamine agonist bromocriptine has no 
effect or impairs working memory (Gibbs and 
D’Esposito, 2005) while a high-dose (2.5 mg) 
of bromocriptine enhances working memory 
(Luciana et al., 1992; Luciana and Collins, 
1997; McDowell, et al., 1998). It is possible 
that a larger dose of dopamine agonists fur-
ther increase postsynaptic dopamine in the 
basal ganglia and prefrontal cortex (Moustafa 
and Gluck, 2011), and thus explain how dif-
ferent doses of dopamine agonists are associ-
ated with dissociable cognitive function.
Another  notable  finding  in  the  Graef 
et al. study is in addition to reward   learning, 
levodopa  also  ameliorates  depression  and 
motor  performance  (as  measured  by  the 
Beck  Depression  Inventory  and  UPDRS 
scales) but has no effect on Mini-Mental State 
Exam (MMSE). This is in line with findings 
that depression and motor performance are 
related to basal ganglia dopamine function 
(Walter et al., 2010), while MMSE scores are 
associated with medial temporal lobe function 
(Ikeda et al., 2008; Ding et al., 2009), which is 
thought to be intact in PD patients.
One unresolved issue in the literature is 
the confounding results regarding the effects 
of dopamine medications on feedback learn-
ing and reversal learning. With regards to 
feedback learning, unlike Graef et al. results, 
other studies have found that the administra-
tion of dopamine medications to PD patients 
impairs or has no effect on feedback learn-
ing (Czernecki et al., 2002; Shohamy et al., 
2006; Jahanshahi et al., 2009). Similarly, stud-
ies have shown that the administration of 
dopamine medications to PD patients either 
enhances or has no effect on reversal learn-
ing (Czernecki et al., 2002; Rutledge et al., 
2009), unlike what Graef et al. have found. 
It is important to note that unlike the Graef 
study, other studies have tested PD patients 
on  multiple  therapies,  including  levodopa 
and dopamine agonists, which might explain 
the different results in these studies. Along the 
same lines, Feigin et al. (2003) have found that 
the administration of levodopa slightly (but 
not significantly) impairs sequence learning in 
PD patients. Sequence learning is a feedback 
learning paradigm in which subjects learn 
to make a “sequence” of motor responses, 
based on corrective feedback. Feigin et al. 
have tested PD patients who were on both 
levodopa and dopamine agonists, but were 
only on levodopa during the time of test-
ing. Differences between the Graef et al. and 
Feigin et al. results could be due to long-term 
effects of the intake of dopamine agonists on 
cognition in the Feigin et al. study.
How would dopamine replacement ther-
apies enhance reward learning but impair 
reversal learning? There are two theories that 
explain Graef et al. results. Frank (2005) argue 
that the basal ganglia direct pathway (along 
with dopamine D1 receptors) is required for 
reward learning, while the indirect pathways 
(along with dopamine D2 receptors) is essen-
tial for punishment learning, which involves 
learning to avoid responses that lead to neg-
ative  feedback.  Frank  further  argues  that 
dopamine   medications increase dopamine Moustafa  Cognitive effects of levodopa in parkinonism
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levels in the basal ganglia and enhance reward 
learning via D1 receptors, but impair punish-
ment learning via D2 receptors. According 
to Frank, following reversal of reward con-
tingencies in the reversal learning task, sub-
jects are more likely to receive more negative 
feedback, and thus an inability to learn from 
negative feedback will lead to reversal learn-
ing impairment in medicated PD patients. 
An alternative theory is proposed by Cools 
et al. (2001), which argue that while the ven-
tral striatum is intact in PD patients, dorsal 
striatum is dysfunctional. Cools et al. further 
argue that reward learning is mediated by the 
dorsal striatum while punishment learning 
by the ventral striatum. According to Cools, 
dopamine medications ameliorate the func-
tion of the dorsal striatum, but overdose the 
ventral  striatum  and  orbitofrontal  cortex 
loop,  and  thus  enhance  reward  learning 
but impair reversal learning. Moustafa and 
Gluck (under review) have recently built a 
computational model showing how overdos-
ing cortical areas impair reversal learning in 
medicated PD patients, as reported by Graef 
et al.
Overall,  Graef  and  colleagues  have 
shown that the administration of levodopa 
monotherapy has both enhancing and del-
eterious effects on cognition in PD patients. 
Future research should investigate the dis-
sociable effects of levodopa vs. dopamine 
agonists on cognition in PD patients. To 
my knowledge, studying differential effects 
of dopamine replacement therapies in PD 
patients  has  been  only  conducted  using 
working memory tasks (Brusa et al., 2003; 
Costa et al., 2003), but not with reward and 
reversal learning paradigms.
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